Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 17/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | KIT | P10721 | 2/20 | 0.50 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | FLT3 | P36888 | 2/20 | 0.50 |
| ▸ | AURKC | Q9UQB9 | 2/20 | 0.50 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1890825 | 0.91 | CYP3A4 (0.76) | CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL1267479 | 0.88 | CYP3A4 (0.80) | CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL1267896 | 0.87 | CYP3A4 (0.75) | CYP1A2CYP3A4CYP2C9CYP2C19KIT | |
| SCHEMBL1893048 | 0.86 | CYP3A4 (0.77) | CYP1A2CYP3A4CYP2C9CYP2C19KIT | |
| SCHEMBL1882053 | 0.86 | CYP3A4 (0.82) | CYP1A2CYP3A4CYP2C9CYP2C19KIT | |
| SCHEMBL1267685 | 0.85 | CYP3A4 (0.65) | CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL1891421 | 0.85 | CYP3A4 (0.79) | CYP1A2CYP3A4CYP2C9CYP2C19KIT | |
| SCHEMBL12899423 | 0.84 | CYP1A2 (0.73) | CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL2112330 | 0.84 | CYP1A2 (0.69) | CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL1888289 | 0.83 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2C9CYP2C19KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101605787-A | Compounds that modulate c-fms and/or c-kit activity and uses thereof | PLEXXIKON INC (US) | 2009-12-16 | — | — | CN | claimed |
| EP-2086972-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2009-08-12 | — | — | EP | claimed |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC | 2009-03-19 | — | — | US | claimed |
| WO-2008064265-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | claimed |
| WO-2008064255-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | claimed |
| EP-4295912-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Daiichi Sankyo, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20190263800-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2019-08-29 | — | — | US | disclosed |
| US-20190263800-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2019-08-29 | — | — | US | disclosed |
| US-10123998-B2 | Kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180055828-A1 | KINASE MODULATION, AND INDICATIONS THEREFOR | DAIICHI SANKYO, INC. | 2018-03-01 | — | — | US | disclosed |
| US-20170247370-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170247370-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON INC. | 2017-08-31 | — | — | US | disclosed |
| US-7893075-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| CN-101605787-A | Compounds that modulate c-fms and/or c-kit activity and uses thereof | PLEXXIKON INC (US) | 2009-12-16 | — | — | CN | disclosed |
| EP-2086972-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC | 2009-03-19 | — | — | US | disclosed |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC | 2009-03-19 | — | — | US | disclosed |
| WO-2008064265-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008064255-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008064255-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10123998-B2 | Kinase modulation, and indications therefor | FLT3, FLT4, FLT1 | CYP1A2 4753/4885CYP3A4 4236/4885CYP2C9 4286/4885 |
| US-20170247370-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | CYP1A2 4297/4885CYP3A4 3847/4885CYP2C9 4122/4885 |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | KIT, FLT3, FLT1 | CYP1A2 4297/4885CYP3A4 3847/4885CYP2C9 4122/4885 |
| US-20180055828-A1 | KINASE MODULATION, AND INDICATIONS THEREFOR | FLT3, FLT4, FLT1 | CYP1A2 4753/4885CYP3A4 4236/4885CYP2C9 4286/4885 |
| US-20190263800-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | CYP1A2 4345/4885CYP3A4 3868/4885CYP2C9 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.